Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Oncology Right
  3. Retevmo (selpercatinib) capsules Right
  4. What are the approved indications for Retevmo® (selpercatinib)?
Search Retevmo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Retevmo ® (selpercatinib) capsules

40 mg, 80 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What are the approved indications for Retevmo® (selpercatinib)?

Selpercatinib is approved in adults with locally advanced or metastatic RET fusion-positive NSCLC or solid tumors and patients ≥12 years with advanced or metastatic RET-mutant MTC or RET fusion-positive thyroid cancer requiring systemic therapy.

US_cFAQ_SEL100_FDA_APPROVAL
US_cFAQ_SEL100_FDA_APPROVAL
en-US

Retevmo®  (selpercatinib) Approved Indications

Retevmo® (selpercatinib) is a kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of 

  • adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test
  • adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy
  • adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), and
  • adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.1

    The indications for MTC, thyroid cancer, and solid tumors are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trial(s).1

    Enclosed Prescribing Information

    RETEVMO® (selpercatinib) capsules, for oral use, Lilly

    Enclosed Patient Information

    RETEVMO® (selpercatinib) patient information, Lilly

    References

    1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

    Date of Last Review: September 15, 2022

    Are you satisfied with this content?

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Accessibility Statement
    • Sitemap

      This site is intended for US Healthcare Professionals only.

      4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      facebook twitter linkedin
      visit www.phactmi.org
      Lilly